1-20 of 76
Anna-Maria Fink
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Moritz Furstenau, Yvonne Thus, Sandra Robrecht, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Julie M.N. Dubois, Julia Von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Michael Baumann, Thomas Noesslinger, Josien Regelink, Ellen C Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Simon Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Eric Eldering, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 842–845.
DOI: https://doi.org/10.1182/blood-2022-164786
Published: 2022
Journal Articles

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Eugen Tausch, Christof Schneider, Moritz Furstenau, Sandra Robrecht, Deyan Yordanov Yosifov, Daniel Mertens, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Clemens-Martin Wendtner, Eric Eldering, Karl-Anton Kreuzer, Matthias Ritgen, Anna-Maria Fink, Kirsten Fischer, Arnon P. Kater, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 839–841.
DOI: https://doi.org/10.1182/blood-2022-163775
Published: 2022
Journal Articles

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia Von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Furstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 834–836.
DOI: https://doi.org/10.1182/blood-2022-163245
Published: 2022
Journal Articles

Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry

Nadine Kutsch, Anna Maria Fink, Anno Federhen, Adam Giza, Sandra Robrecht, Janina Stumpf, Andrea Stoltefuß, Ursula Vehling-Kaiser, Michael Koenigsmann, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Thomas Illmer, Rudolf Schlag, Steffen Dörfel, Tobias Gaska, Michael G. Kiehl, Kirsten Fischer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 140 (Supplement 1): 9879–9881.
DOI: https://doi.org/10.1182/blood-2022-169956
Published: 2022
Journal Articles

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Clinical Trials & Observations
Henriette Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna L. Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 139 (9): 1318–1329.
DOI: https://doi.org/10.1182/blood.2021013208
Published: 2022
Includes: Supplemental data
Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Clinical Trials & Observations
Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Julia von Tresckow, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Lothar Müller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 139 (2): 177–187.
DOI: https://doi.org/10.1182/blood.2021010845
Published: 2022
Includes: Supplemental data
Journal Articles

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations

Clinical Trials & Observations
Paula Cramer, Eugen Tausch, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Moritz Fürstenau, Petra Langerbeins, Othman Al-Sawaf, Benedikt W. Pelzer, Anna Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (19): 1805–1816.
DOI: https://doi.org/10.1182/blood.2020010484
Published: 2021
Includes: Supplemental data
Journal Articles

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Moritz Fürstenau, Sandra Robrecht, Can Zhang, Julia Von Tresckow, Carsten Utoft Niemann, Arnon P. Kater, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek, Barbara Eichhorst
Journal: Blood
Blood (2021) 138 (Supplement 1): 2639.
DOI: https://doi.org/10.1182/blood-2021-147790
Published: 2021
Journal Articles

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Moritz Fürstenau, Anke Schilhabel, Sandra Robrecht, Can Zhang, Julia Von Tresckow, Carsten Utoft Niemann, Arnon P. Kater, Eugen Tausch, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Marinus H.J. Van Oers, Caspar Da Cunha-Bang, Christian H. Geisler, Stephan Stilgenbauer, Monika Brüggemann, Michael Hallek, Matthias Ritgen, Barbara Eichhorst
Journal: Blood
Blood (2021) 138 (Supplement 1): 72.
DOI: https://doi.org/10.1182/blood-2021-147729
Published: 2021
Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Niemann, Arnon P. Kater, Moritz Fürstenau, Julia Von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jaeger, Henrik Frederiksen, Maria B.L. Leijs, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (Supplement 1): 71.
DOI: https://doi.org/10.1182/blood-2021-146161
Published: 2021
Journal Articles

Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older

Florian Simon, Adam Giza, Sandra Robrecht, Anna-Maria Fink, Paula Cramer, Julia Von Tresckow, Moritz Fürstenau, Valentin Goede, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Clemens-Martin Wendtner, Barbara Eichhorst, Kirsten Fischer, Michael Hallek, Othman Al-Sawaf
Journal: Blood
Blood (2021) 138 (Supplement 1): 1552.
DOI: https://doi.org/10.1182/blood-2021-150698
Published: 2021
Journal Articles

MARCKS affects cell motility and response to BTK inhibitors in CLL

Laura Beckmann, Valeska Berg, Clarissa Dickhut, Clare Sun, Olaf Merkel, Johannes Bloehdorn, Sandra Robrecht, Marc Seifert, Alexandra da Palma Guerreiro, Julia Claasen, Stefan Loroch, Matteo Oliverio, Chingiz Underbayev, Lauren Vaughn, Daniel Thomalla, Malte F. Hülsemann, Eugen Tausch, Kirsten Fischer, Anna Maria Fink, Barbara Eichhorst, Albert Sickmann, Clemens M. Wendtner, Stephan Stilgenbauer, Michael Hallek, Adrian Wiestner, René P. Zahedi, Lukas P. Frenzel
Journal: Blood
Blood (2021) 138 (7): 544–556.
DOI: https://doi.org/10.1182/blood.2020009165
Published: 2021
Includes: Supplemental data
Journal Articles

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

Clinical Trials & Observations
Moritz Fürstenau, Anna Maria Fink, Anke Schilhabel, Jonathan Weiss, Sandra Robrecht, Robert Eckert, Javier de la Serna, Marta Crespo, Marta Coscia, Candida Vitale, Sebastian Böttcher, Gesche Weppner, Matthias Ritgen, Stephan Stilgenbauer, Eugen Tausch, Kirsten Fischer, Michael Hallek, Barbara Eichhorst, Monika Brüggemann, Carmen D. Herling
Journal: Blood
Blood (2021) 137 (16): 2267–2271.
DOI: https://doi.org/10.1182/blood.2020008609
Published: 2021
Includes: Supplemental data
Journal Articles

Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Paula Cramer, Carmen D. Herling, MD PhD, Julia Von Tresckow, MD, Elisabeth Lange, MD, Sebastian Böttcher, MD PhD, Michael G. Kiehl, MD PhD, Martin Dreyling, MD, Ulrich Jaeger, Michael Gregor, MD, Ursula Vehling-Kaiser, MD, Matthias Ritgen, MD, Jan Dürig, MD, Eugen Tausch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Valentin Goede, MD, Michael Hallek, MD, Barbara Eichhorst, MD, Petra Langerbeins, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
DOI: https://doi.org/10.1182/blood-2020-139242
Published: 2020
Journal Articles

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, Julia Von Tresckow, MD, Anna-Maria Fink, MD, Gracia Braun, Sandra Robrecht, PhD, Can Zhang, PhD, Eugen Tausch, MD, Lothar Müller, MD, Wolfgang Knauf, MD, Othman Al-Sawaf, MD, Benedikt Pelzer, MD, Petra Langerbeins, MD, Kirsten Fischer, MD, Karl-Anton Kreuzer, MD, Matthias Ritgen, MD, Michael Kneba, MDPhD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Barbara Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
DOI: https://doi.org/10.1182/blood-2020-134827
Published: 2020
Journal Articles

Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Cameron Wilson, Maneesh Tandon, MD, Travers Ching, Anna-Maria Fink, MD, Matthias Ritgen, MD, Eugen Tausch, MD, Karl-Anton Kreuzer, MD, William Schary, PhD, Clemens-Martin Wendtner, Barbara Eichhorst, MD, Stephan Stilgenbauer, MD, Yanwen Jiang, Michael Hallek, Kirsten Fischer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
DOI: https://doi.org/10.1182/blood-2020-136977
Published: 2020
Journal Articles

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Heng Pan, PhD, Loïc Renaud, MD MSc, Ronan Chaligne, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Daniel Mertens, PhD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Chao Zhang, PhD, Doron Betel, PhD, Andreas Gnirke, Marcin Imielinski, Jerome Moreaux, PhD, Michael Hallek, Alexander Meissner, PhD, Stephan Stilgenbauer, MD, Catherine J. Wu, MD, Olivier Elemento, PhD, Dan A. Landau, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
DOI: https://doi.org/10.1182/blood-2020-136830
Published: 2020
Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Clinical Trials & Observations
Eugen Tausch, Christof Schneider, Sandra Robrecht, Can Zhang, Anna Dolnik, Johannes Bloehdorn, Jasmin Bahlo, Othman Al-Sawaf, Matthias Ritgen, Anna-Maria Fink, Barbara Eichhorst, Karl-Anton Kreuzer, Maneesh Tandon, Kathryn Humphrey, Yanwen Jiang, William Schary, Lars Bullinger, Daniel Mertens, Michele Porro Lurà, Michael Kneba, Hartmut Döhner, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer
Journal: Blood
Blood (2020) 135 (26): 2402–2412.
DOI: https://doi.org/10.1182/blood.2019004492
Published: 2020
Includes: Supplemental data
Journal Articles

High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

Clinical Trials & Observations
Othman Al-Sawaf, Esther Lilienweiss, Jasmin Bahlo, Sandra Robrecht, Anna-Maria Fink, Michaela Patz, Maneesh Tandon, Yanwen Jiang, William Schary, Matthias Ritgen, Eugen Tausch, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek, Karl-Anton Kreuzer
Journal: Blood
Blood (2020) 135 (11): 866–870.
DOI: https://doi.org/10.1182/blood.2019003451
Published: 2020
Includes: Supplemental data
Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Kirsten Fischer, MD, Matthias Ritgen, Othman Al-Sawaf, MD, Sandra Robrecht, PhD, Maneesh Tandon, MD, Anna-Maria Fink, MD, Anke Schilhabel, PhD, Thomas Stübig, MD, Monika Brüggemann, MD, Yanwen Jiang, PhD, William Schary, PhD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Eugen Tausch, Karl-Anton Kreuzer, MD PhD, Anton W Langerak, PhD, Valentin Goede, MD, Sebastian Böttcher, MD, Stephan Stilgenbauer, MD, Michael Kneba, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 36.
DOI: https://doi.org/10.1182/blood-2019-125825
Published: 2019